{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:40:07Z","timestamp":1757544007617},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,8,15]],"date-time":"2008-08-15T00:00:00Z","timestamp":1218758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> This post\u2010marketing study aimed to record rates of retention, adverse effects and efficacy of leflunomide in the treatment of rheumatoid arthritis (RA). The secondary objectives were to make a semi\u2010quantitative assessment of response to treatment and to examine the effect of a loading dose on adverse events and treatment duration.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Rheumatologists in New Zealand contributed to a prospective leflunomide treatment registry. Baseline data were collected on leflunomide initiation and information about treatment experience was sought every 6\u2003months. Each patient was followed for 2\u2003years. Kaplan\u2013Meier analysis was used to evaluate differences in stopping rates between lack of efficacy and adverse effects. Hazard analysis was used to evaluate the effect of using a loading dose on retention rate.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Three hundred and eight patients were enrolled in the study; complete follow\u2010up data were available for 244 patients. Retention of patients on leflunomide was 64% at 12\u2003months and 49.4% at 2\u2003years. Reasons for stopping were adverse events (54 patients), loss of effect (25 patients) and miscellaneous reasons (14 patients). Use of a loading dose had no effect on retention; there was no difference in treatment duration between those who stopped from adverse effects or loss of efficacy.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Leflunomide was effective in treating RA in a group that had longer duration of disease and greater prior use of disease\u2010modifying agents than the groups studied in clinical trials. Rates of withdrawal were lower than those reported in other post\u2010marketing studies, but were higher than those from phase III clinical trials.<\/jats:p>","DOI":"10.1111\/j.1445-5994.2008.01792.x","type":"journal-article","created":{"date-parts":[[2008,8,16]],"date-time":"2008-08-16T01:21:20Z","timestamp":1218849680000},"page":"95-102","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Leflunomide use in New Zealand. A national prospective post\u2010marketing study"],"prefix":"10.1111","volume":"39","author":[{"given":"D. H. N.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. V.","family":"Lynskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. B. B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,3,31]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780381111"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09403-3"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.21.2542"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.6.655"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U"},{"key":"e_1_2_7_7_2","first-page":"80","article-title":"Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials","volume":"23","author":"Martin K","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11452"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02131.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.10.944"},{"key":"e_1_2_7_11_2","first-page":"115","article-title":"Effectiveness and safety of leflunomide in the clinical practice. A different experience","volume":"25","author":"Pisoni L","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241060-00003"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(05)80305-X"},{"key":"e_1_2_7_15_2","first-page":"168","article-title":"Leflunomide in rheumatoid arthritis in daily practice: treatment discontinuation rates in comparison with other DMARDs","volume":"24","author":"Bettembourg\u2010Brault I","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1252"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1297-319X(02)00397-4"},{"key":"e_1_2_7_18_2","first-page":"235","article-title":"Rheumatoid arthritis treatment with weekly leflunomide: an open\u2010label study","volume":"31","author":"Jaimes\u2010Hernandez J","year":"2004","journal-title":"J Rheumatol"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2008.01792.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2008.01792.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T21:58:10Z","timestamp":1695851890000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2008.01792.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1445-5994.2008.01792.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2008.01792.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"2009-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}